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Abstract
Inflammatory rheumatic diseases are generally multifaceted 
disorders and, therefore, measurement of multiple outcomes is 
relevant to most of these diseases. Developments in outcome 
measures in the rheumatic diseases are promoted by the 
development of successful treatments. Outcome measurement will 
increasingly deal with measurement of low levels of disease activity 
and avoidance of disease consequences. It is an advantage for 
patient management and knowledge transfer if the same outcomes 
are used in practice and in trials. Continuous measures of change 
are generally the most powerful and, therefore, are preferred as 
primary outcomes in trials. For daily clinical practice, outcome 
measures should reflect the patients' state and have to be easily 
derivable. The objective of this review is to describe recent 
developments in outcome measures for inflammatory rheumatic 
diseases for trials and clinical practice, with an emphasis on 
rheumatoid arthritis.
Introduction
In inflammatory rheumatic diseases, disease outcomes can be 
recognized as manifestations reflecting the underlying disease 
process (synovitis, acute phase response, pain), measures of 
discomfort (pain, fatigue, stress), measures of disability, 
measures reflecting organ damage, and eventually death. 
Costs are a non-medical outcome, which are driven by the 
disease as well as by health care and society. Outcome 
measures have applications in clinical trials and observational 
studies, as well as in clinical practice. It is an advantage for 
patient management and knowledge transfer if the same 
outcomes are used in practice and in trials. However, to be 
useful in practice, outcome measures should be easily derived. 
Meanwhile, patient-reported outcomes have been established 
in rheumatic diseases, complementary to laboratory measures 
(disease markers, images) and examination findings.
Recent developments in outcome measures in the rheumatic 
diseases have been promoted by the development of
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successful treatments in the past decade. For diseases for 
which there already was effective treatment available, new, 
more effective or less toxic treatments have been tested and 
introduced [1]. For diseases for which there was no effective 
treatment, new treatments have been developed and shown 
to be effective [1]. A well-known example of this is anti-tumor 
necrosis factor for the treatment of rheumatoid arthritis (RA) 
and ankylosing spondylitis. The ultimate goal of pharmaco­
logical treatment in the inflammatory rheumatic diseases 
nowadays is to reach and sustain remission, including the 
complete suppression of inflammation and pain and the 
prevention of excess disability and organ damage. However, 
sustained remission, not to mention cure, is still difficult to 
reach.
The objective of this review is to describe recent develop­
ments in outcome measurement for inflammatory rheumatic 
diseases for trials and clinical practice, with an emphasis on 
RA.
Outcomes in rheumatology
Multiple outcomes
Inflammatory rheumatic diseases are generally multifaceted 
disorders and, therefore, measurement of multiple outcomes 
is relevant to most of these diseases. Also, the complexity of 
the pathogenic processes underlying inflammatory rheumatic 
diseases leads to difficulty in finding a single representative 
outcome measure. Relevant areas of outcome measurement 
are disease activity, discomfort, disability, damage and death.
Proxy outcomes
Proxy outcomes are frequently used in rheumatology. 
Outcomes generally are manifestations reflecting the under­
lying pathogenic process, measures of discomfort, measures 
of disability, measures reflecting organ damage, and even­
tually death. Objectively measured organ damage probably is
ACR =  American College of Rheumatology; CDAI =  Clinical Disease Activity Index; DAS =  Disease Activity Score; DMARD =  disease-modifying 
antirheumatic drug; ESR =  erythrocyte sedimentation rate; EULAR =  European League Against Rheumatism; HAQ =  Health Assessment Question­
naire; OMERACT =  Outcome Measures in RA Clinical Trials; RA =  rheumatoid arthritis; RADAI =  RA Disease Activity Index; RAPID =  Routine 
Assessment of Patient Index Data; RCT =  randomized, controlled trial; SDAI =  Simplified Disease Activity Index; SF =  Short Form.
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the best endpoint measure for rheumatic disorders. However, 
organ damage may take some time to complete and, quite 
notably, is a state to be prevented. Therefore, organ damage 
cannot always be used as an outcome measure, but instead it 
is inferred from precursors or the disease process 
supposedly leading to the damage. Biomarkers and technical 
imaging techniques are used to try to obtain a more precise 
measurement of the disease process and of damage, 
especially at subclinical levels of disease [2-4]. For example, 
in RA, bone edema made visible by imaging techniques may 
be regarded as a precursor of bone erosion [3].
Disease activity
In rheumatic disorders, the manifestations that are measured 
depend on the disease that is studied, and may comprise 
acute phase reactants, swollen and tender joint counts, pain, 
fatigue, morning stiffness, count of inflamed entheses, and so 
on. These manifestations comprise more or less objective 
signs (for example, counts of the number of swollen joints), 
naturally subjective symptoms (for example, pain, fatigue), 
and laboratory values (for example, erythrocyte sedimentation 
rate (ESR), and C-reactive protein levels). Disease activity in 
RA is a good example of where manifestations of the 
underlying pathogenic process have been combined in a 
pooled measure to increase its validity and precision 
(Table 1) [5]. The Disease Activity Score (DAS; and its 
modified version DAS28) consist of a combination of the 
number of tender joints, the number of swollen joints, ESR 
and a global assessment rating by the patient and are 
extensively validated [6]. The Simplified Disease Activity Index 
(SDAI) and the Clinical Disease Activity Index (CDAI) are 
derivations that omit the weighting (SDAI) and also omit a 
laboratory value (CDAI) [7].
The RA Disease Activity Index (RADAI) is a self-report 
questionnaire of symptoms, including a self-assessed joint 
count [8]. The Routine Assessment of Patient Index Data 
(RAPID) and the Patient Activity Scale (PAS) are patient self­
report questionnaires consisting of the three patient-reported 
outcomes of the core set of endpoints for RA clinical trials: 
pain, patient global assessment of disease activity, and the 
Health Assessment Questionnaire (HAQ) [9,10]. The RAPID 
may also include a RADAI-style self-rated joint count [9]. The 
DAS, DAS28, CDAI and SDAI include a single patient-rated 
item on global assessment.
Discomfort and disability
Symptoms of the disease may cause discomfort to the 
patient. In rheumatic diseases, pain and fatigue are important 
sources of discomfort that also lead to disability. Due to the 
involvement of the musculoskeletal system, disability obviously 
is a central concept in rheumatic disorders and there are 
many disorder-specific questionnaires available that measure 
the level of patient-perceived disability. The outstanding 
example of this is the disability index of the HAQ, which was 
developed for RA but is also applied in other rheumatic
disorders [11,12]. Most emphasis is placed on ‘patient- 
reported outcomes' to measure patient-perceived disability.
Damage
Organ damage and death may be considered as ‘hard' 
outcome measures in rheumatology. Progression of joint 
damage is a well-established outcome for trials in 
inflammatory joint diseases. In RA, measurement of joint 
damage of the hands and feet was deemed appropriate if 
trials last 12 months or longer, but with the current effective 
medication it may also be appropriate to measure joint 
damage after just 3 or 6 months. The eventual progression of 
joint damage can be rated by applying a standard scoring 
system, such as the Sharp-vanderHeijde score applied to 
plain X-rays of the hands and feet in RA [13]. The outcome 
measure can be the progression of raw scores or the number 
of patients that progress more than the smallest detectable 
change - for example, all patients that progress more than 
6 points (Figure 1) [14]. Using the proportion of patients with 
progression of joint damage in two (treatment) groups favors 
the calculation of relative risk as an effect measure. Relative 
risks are easy to combine in meta-analyses.
Death
Mortality in RA was explored initially in 1953 and since then 
numerous other studies have investigated mortality among 
patients with RA, with most demonstrating reduced life 
expectancy ranging from 5 to 15 years compared with the 
general population [15,16]. In addition to RA, several other 
inflammatory rheumatic disorders are associated with 
increased mortality, notably psoriatic arthritis, and ankylosing 
spondylitis [16]. Rheumatic disorders infrequently appear as 
the cause of death on death certificates. Rather, what is 
regarded as the immediate cause of death, such as cardio­
vascular disease, renal failure or pulmonary infection, is noted. 
At least for RA it appears that mortality has not improved over 
time [17]. Observing improving trends of survival over calendar 
time in rheumatic disorders is an important outcome of the 
quality of rheumatology care for these patients. Death (survival 
time) may also be a relevant outcome for clinical trials that 
include patients who are treated for life-threatening 
complications of their rheumatic disorder [18].
Quality of life
Quality of life in the context of outcome measurement is 
generally handled as a descriptive term that refers to people's 
emotional, social and physical wellbeing, and their ability to 
function in the ordinary tasks of living. In arthritis, the most 
common used measure covering these items is the Short 
Form (SF)-36 questionnaire on general health, which has also 
been validated for RA [19]. The advantage of the SF-36 is 
that a broader concept of health is measured and the SF-36 
can be compared across difference conditions. The term 
‘quality-of-life measures' is frequently used interchangeably 
with the term ‘patient-reported outcomes'. However, instead 
of using the term ‘quality-of-life', what can generally be
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Table 1
Pooled indices developed for rheumatoid arthritis
Name Year Form Aspect Laboratory Symptoms Global assessments Joint examination Function
Lansbury 1956 Continuous State ESR MS Fatigue Pain* Grip
Pooled 1977 Continuous State ESR MS TJC Grip Func. index
ARA remission 1981 Dichotomy State ESR MS Fatigue SJC TJC
Mallya 1981 Continuous State ESR, Hb MS Pain RAI Grip
IDA 1983 Continuous State ESR, Hb MS TJC
New IDA 1990 Continuous State ESR, Hb Pain RAI Grip HAQ
Stoke 1990 Continuous State ESR, CRP MS RAI, PIPs
Scott 1990 Continuous State ESR MS Pain RAI
DAS 1990 Continuous State ESR PGA+ SJC RAI
Paulus 1990 Dichotomy Change ESR MS PGA DGA SJC TJC
RADAI* 1995 Continuous State MS Pain PGA GH TJC
DAS 2 8 1995 Continuous State ESR PGA+ SJC TJC
ACR response 1995 Dichotomy Change ESR Pain PGA DGA SJC TJC HAQ
EULAR response 1995 T richotomy Change and state ESR PGA SJC TJC
SDAI 2003 Continuous State CRP PGA DGA SJC TJC
CDAI 2005 Continuous State PGA DGA SJC TJC
PASS* 2005 Continuous State Pain PGA HAQ
RAPID* 2006 Continuous State Pain PGA HAQ
ACR ‘hybrid' 2007 Continuous Change and state ESR Pain PGA DGA SJC TJC HAQ
Pooled indices developed for the assessment of disease activity in rheumatoid arthritis, adapted after [5], *Aspirine need as proxy for pain. f DAS and DAS28 were developed with a global 
General Health rating, though PGA is more broadly used than GH now. *Self-assessed. ACR, American College of Rheumatology; ARA, American Rheumatism Association; CDAI, Clinical 
Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; DGA, doctor global assessment of disease activity; ESR, erythrocyte sedimentation rate; EULAR, European 
League Against Rheumatism; GH, general health; Grip, grip strength; HAG, Health Assessment Questionnaire disability index; Hb, hemoglobin level; IDA, Index of Disease Activity; MS, morning 
stiffness; PASS, Patient Acceptable Symptom State; PGA, patient global assessment of disease activity; PIP, proximal interphalangeal joints; RADAI, RA Disease Activity Index; RAI, Ritchie 
Articular Index; RAPID, Routine Assessment of Patient Index Data; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count.
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F igu re  1
Cumulative probability plots of individual 1-year radiographic 
progression scores in 135 rheumatoid arthritis patients who were 
participating in the Combinatietherapie Bij Reumatoide Artritis 
(COBRA) trial (67 patients in the monotherapy group (circles) and 68 
patients in the combination therapy group (triangles)). Reprinted from 
[14] with permission of John Wiley & Sons, Inc.
described is what is measured: for example, emotional well­
being, functioning, or disability. Satisfaction of a person with 
certain aspects of life, however, is a non-medical outcome 
and is not generally associated with a lasting influence of 
medical interventions.
Outcome measures
Common outcome measures
The use of core sets of outcome measures greatly enhanced 
the comparability of trials in rheumatic disorders. Because of 
the many manifestations involved in rheumatic disorders, 
there had been much variability in choice of trial endpoints 
and in the way they were measured. A process leading to 
consensus and standardization of outcome measures for 
trials was started for RA, notably by the Outcome Measures 
in RA Clinical Trials (OMERACT) initiative [20]. This agreed 
on the use of a ‘core set' of measures to be used, at a 
minimum, in randomized, controlled trials (RCTs) on disease- 
modifying antirheumatic drugs (DMARDs) in RA [20]. This 
core set comprises six measures representing joint inflamma­
tion, one measure of disability, and the measurement of joint 
damage in trials lasting 12 months or longer (Table 2). Physical 
disability or function is a key concept in rheumatic disorders. 
Several validated questionnaires to measure disability are 
available, but the most common questionnaire in clinical trials 
of RA and other rheumatic disorders is the HAQ.
Within the OMERACT framework, consensus on common 
outcome measures for other rheumatic disorders has also 
been attempted. Except for RA, similar approaches to 
establish core sets of measures, disease activity measures, 
and response criteria for RCTs have been made for several 
other rheumatic diseases, notably psoriatic arthritis and 
ankylosing spondylitis (Table 2) [20-23]. In contrast to RA, 
where the target organ system may be defined as the joints, 
these diseases have multiple manifestations in multiple organ 
systems; for example, manifestations of psoriatic arthritis may 
include arthritis, psoriasis, dactylitis, nail involvement, 
enthesitis, and spondylitis.
Composite endpoint measures
In the context of multiple outcome measures, and without a 
gold standard or obvious choice of measure to be used as 
primary outcome, composite endpoint measures are useful to 
avoid multiple testing and to increase statistical power. An 
advantage of the reduction of measurement error by 
combination of measures is that an index can be more 
responsive than its parts. The main disadvantages of 
composite measures are concerns over validity and practical 
problems such as interpretation and computational 
difficulties. The validity of an index depends on the validity of 
the measures that are included and their appropriate 
weighting. The interpretation of an index becomes easier 
when more information from validity studies (for example, 
discriminative or predictive) is available and when an index 
has become familiar. The composite indexes in use may fall in 
the categories of state measures and response measures.
Assessment of state
The most popular state index for use in RA is the DAS and its 
modified version DAS28 (Table 3) [24,25]. The DAS is a 
continuous measure reflecting the level of underlying rheu­
matoid inflammation. It was developed using decisions on 
DMARD therapy as an external standard of high and low 
disease activity. The DAS includes information from tender 
and swollen joint counts, ESR and a patient global rating, with 
the statistical advantage of having a Gaussian distribution.
The DAS28 is similar to the DAS, includes reduced joint 
counts and has a different range. The DAS28 ranges from 0 
to 10: a DAS28 <3.2 is equated with ‘ low' disease activity 
and a DAS28 >5.1 is called ‘high' disease activity [26,27].
Similar kinds of disease activity scores, in part using similar 
approaches, have been developed not only for RA (SDAI) 
and ankylosing spondylitis (Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI)), but also for systemic lupus 
erythematosus (Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI)), and systemic sclerosis [7,28-30].
Assessment of change
The two response measures most frequently used for testing 
DMARDs in RA are the European League Against Rheuma-
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Tab le  2
C ore se ts  o f tr ia l ou tcom e  m easures
Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis
Acute phase reactants Acute phase reactants Acute phase reactants
Swollen joint count Joint counts Joint counts
Tender joint count Axial skeleton Enthesitis
Observer global rating Observer global rating Spinal mobility
Patient global rating Dactylitis Stiffness
Patient pain rating Enthesitis Patient global rating
Physical function Psoriasis extent Patient pain rating
Joint damage by X-ray Nail involvement 
Patient pain rating 
Patient itching rating 
Physical function 
Joint damage by X-ray
Physical function
Trial outcome measures deemed important for disease modifying anti-rheumatic therapies in 
and ankylosing spondylitis [23].
rheumatoid arthritis [20,21], psoriatic arthritis [22],
Tab le  3
EULAR response crite ria  and th e  d isease  ac tiv ity  score  in  rheum a to id  a rth ritis
Change in DAS or DAS28 attained
DAS or DAS28 attained at endpoint >1.2 0.6 <  A < 1.2 <0.6
‘High' DAS >3.7 DAS28 >5.1 Moderate No
‘Moderate' 2.4 <  DAS < 3.7 3.2 <  DAS28 < 5.1 Moderate Moderate
‘Low' DAS <2.4 DAS28 <3.2 Good Moderate
Calculation of the disease activity scores DAS and DAS28 to assess joint inflammation in rheumatoid arthritis and the response criteria of the 
European League against Rheumatism (EULAR) [24-27]. The EULAR criteria use the level of disease activity at the endpoint as well as the change 
at the endpoint for determining a patient as a good, moderate or non-responder. DAS28 =  0.56 x  (VTJC28) + 0.28 x  (VSJC28) + 0.70 x  (lnESR) 
+ 0.014 x  GH; DAS =  0.54 x  (VRAI) + 0.065 x  SJC44 + 0.33 x  (lnESR) + 0.0072 x  GH. DAS, Disease Activity Score; ESR, erythrocyte 
sedimentation rate; GH, general health; RAI, Ritchie Articular Index; SJC, swollen joint count; TJC, tender joint count.
tism (EULAR) response criteria (Table 3) and the American 
College of Rheumatology (ACR) improvement criteria (Table 4) 
[21,26]. The ACR criteria are a dichotomized measure of 
change, whilst the EULAR criteria include change as well as 
the level of disease activity reached. Despite their different 
approaches, ACR and EULAR criteria generally lead to 
similar results [27]. The EULAR response criteria define the 
patient as a good, moderate or non-responder, dependent on 
both the magnitude of improvement according to the DAS or 
DAS28 and the absolute level of the DAS reached [26,27]. 
The ACR improvement criteria define a patient as a 
responder if there is at least 20% improvement in both tender 
and swollen joint counts, and in three of the following five 
measures: pain, patient global assessment, physician global 
assessment, disability, and an acute phase reactant [21]. The
ACR improvement criteria were designed to optimally 
discriminate placebo from drug in clinical trials. To accom­
modate the larger effects with newer medications, ACR50% 
and 70% criteria are also used. However, these cut-off points 
are not endorsed as a primary outcome measure [32]. To 
accommodate testing differences between two effective 
medications that are generally smaller than a difference 
between placebo and a medication, a revised version of the 
ACR criteria (‘ACR-hybrid') was developed [33].
Response criteria for use in RCTs have also been developed 
and applied in psoriatic arthritis (Psoriatic Arthritis Response 
Criteria (PsARC)), ankylosing spondylitis (Ankylosing Spon­
dylitis Assessment Score (ASAS)) and osteoarthritis (Osteo­
arthritis Research Society International (OARSI)) [34-36].
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Tab le  4
ACR im provem en t crite ria  fo r  use in rheum ato id  a rth ritis
A patient is classified as improved if there is at least 20% improvement 
in five out of seven core-set variables, the first two required:
Tender joint count
Swollen joint count
Acute phase reactant
Patient rating of pain
Patient global assessment of disease activity 
Observer global assessment of disease activity 
Physical disability 
ACR, American College of Rheumatology.
Outcome measurement in trials
Change or state measures?
Currently, there is a movement from change endpoints to 
endpoints with absolute values. In contrast to change 
endpoints, when using absolute measures there is no need to 
choose cut-off points, and the difference between two drugs 
or between a drug and placebo can readily be interpreted in 
terms of the endpoint measure. Continuous measures are 
flexible for deriving other endpoints. Depending on what is 
considered appropriate, one could define in advance whether 
to use the absolute change in the measure, the percentage of 
patients below a cut-off point, time-to-reach that cut-off point, 
the number of visits below a cut-off point, and so on.
Dichotomous or continuous endpoints?
One of the advantages of dichotomized improvement criteria 
is that the outcome is clearly expressed as a yes or no 
response, or success or failure. This probably led to the 
dichotomization of originally continuous measures for use as 
trial endpoints, such as the 1.2 improvement in DAS28. The 
disadvantages of this approach include not only that power is 
lost when dichotomizing a continuous or ordinal measure, but 
also that meaning is lost.
The more attractive alternative would be to use the DAS as a 
continuous endpoint. If the underlying endpoint is continuous 
(disease activity, ability), a meaningful cut-off point should be 
chosen if dichotomizations are preferred. Examples of such 
outcome measures are the percentage of RA patients 
reaching low disease activity (DAS28 <3.2), and the 
percentage of RA patients with a progression of joint damage 
larger than the smallest detectable change in X-ray score. 
Figure 1 illustrates an example where the smallest detectable 
change is determined as a 4-point change in the Sharp- 
vanderHeijde score [37]. This approach is especially appro­
priate if the outcome measure represents a target of 
treatment. A similar approach used for patient questionnaires 
is the definition of a minimal important change using patient
panels. The percentage of patients exceeding this predefined 
minimal important change is used as the outcome measure.
An alternative that better reflects treatment goals is the 
concept of ‘patient acceptable symptom state', which is also 
assessed using patient panels [38,39]. However, power is 
generally lost when dichotomizing a continuous measure. 
Therefore, it may be worthwhile to use a continuous measure 
as primary outcome, and use clinically useful dichotomi- 
zations as informative secondary outcomes.
Minimal important change or remission?
Reaching remission, or a state of low disease activity, is the 
ultimate goal of treatment in rheumatic disorders. Concep­
tually, remission is more appropriate than change as the 
endpoint. However, remission is not always a target that can 
be reached and a state of low disease activity could be used 
instead. A well-known example is the Minimal Disease Activity 
State (MDAS), which was developed for RA and can be 
calculated alternatively using the DAS28 or the ACR core-set 
measures [40].
The problem still is that remission is ill-defined and the 
absence of manifestations is difficult to measure. Also, it is 
unclear how far the underlying disease process is silent in the 
absence of manifestations. If minimal important change is 
used, information on the magnitude of change is lost and 
change does not reflect the target of treatment. The target is 
not to induce change per se, but rather change is necessary 
to reach the target of low disease activity or remission.
Reporting of disease activity in trials
Even with commonly used outcome measures, trial publi­
cations still differ in their reporting. Consequently, it is still 
difficult to compare trial results and to combine them in a 
meta-analysis. A recent initiative by the ACR and EULAR has 
provided recommendations on disease activity reporting in 
clinical trials [41]. If these recommendations are followed, it is 
warranted that similar and useful information can be derived 
from trial reports, irrespective of the primary outcome 
measure used. Important considerations are the reporting on 
disease activity response as well as states, and the inclusion 
of time (Table 5).
Outcome measurement in practice
In daily practice, outcomes should be measures of state 
rather than measures of change. The reason is that the goal 
of therapy is to reach low disease activity or even remission; 
thus, a physician should primarily know about the state the 
patient is in. A continuous measure of disease activity is most 
useful to measure changes (of the patient's state). Most 
available indices are subdivided into levels of ‘low', 
‘moderate', and ‘high' disease activity, analogous to the DAS 
and DAS28 (Table 3). However, states of remission or a 
‘patient acceptable symptom state' also provide meaningful 
endpoints in practice.
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Tab le  5
EULAR/ACR co lla b o ra tive  recom m enda tions fo r  d isease  a c tiv ity  repo rting  in  c lin ica l tr ia ls
Point Description
1 Each trial should report the disease activity response and disease activity states
1a Response: ACR (ACR20, ACR50, ACR70: ideally also ACR Hybrid, after successful prospective validation in clinical trials) and 
EULAR response criteria (good, moderate and non-responders)
1b States: composite measures of disease activity should be used as outcome measures and with cut-off points to define various disease 
activity states: they include DAS/DAS28, CDAI, and SDAI; appropriate descriptive statistics of the baseline, the endpoint and change 
of the composite indices should be reported
2 Each trial should report the appropriate descriptive statistics of the baseline, the endpoint, and change of the single variables included 
in the core set
3 Each trial should report the baseline disease activity levels
4 Each trial should report the percentage of patients achieving a low disease activity state and remission
4a Definitions that should be used for low disease activity include cut-off points for low disease activity for DAS/DAS28, CDAI, SDAI, and 
MDA
4b Definitions that could be used for remission include preliminary ARA remission criteria and respective cut-off points for DAS/DAS28, 
CDAI, and SDAI
5 Each trial should report the time to onset of the primary outcome (a particular response or a certain disease activity state)
6 Each trial should consider and report the sustainability of the primary outcome (as opposed to evaluating it at a single predefined time 
point during the trial)
7 Each trial should report on fatigue
ACR, American College of Rheumatology; ARA, American Rheumatism Association; CDAI, Clinical Disease Activity Index; DAS, Disease Activity 
Score; EULAR, European League Against Rheumatism; MDA, Minimal Disease Activity; SDAI, Simplified Disease Activity Index. Reprinted from 
[41] with permission of John Wiley & Sons, Inc.
General treatment principles in RA are that: patients who may 
have RA are to be detected and referred early, RA should be 
treated immediately, tight control of disease activity should be 
applied, and, in addition, treatment should be individually 
tailored considering risk-benefit [42]. These principles are 
reflected in treatment guidelines of the ACR and EULAR 
[43,44].
In practice, outcome measurement is useful for treatment 
indication and for tight control. In the ACR recommendations 
for the use of nonbiologic and biologic DMARDs, the choice 
for treatment is steered by the presence of features of poor 
prognosis, disease activity, and disease duration [43]. As 
there currently are many appropriate disease activity indices 
available, it was considered that disease activity can be 
judged using the available definitions of ‘ low', ‘moderate', and 
‘high' disease activity (Table 6).
Several trials have shown the beneficial effect of a tight 
control strategy in the treatment of RA, notably the Tight 
Control for Rheumatoid Arthritis (TICORA), Computer 
Assisted Management for Early Rheumatoid Arthritis 
(CAMERA), Treatment Strategies for RA (BeST) and 
Systematic Monitoring of RA Disease Activity (TRAC) studies 
[45-48]. There is also evidence to suggest that monitoring of 
disease activity without a treatment protocol confers no major
improvement over usual care [48]. Therefore, the tight control 
principle can be understood as a protocol based on an 
objective measure of disease activity that determines whether 
treatment is escalated or reduced; a low threshold of 
continuing disease activity triggers a treatment change; and 
treatment decisions are made frequently (monthly rather than 
every 3 months) [42]. So far, disease activity indices, notably 
the DAS, have been used in tight control studies.
The RADAI and the RAPID are disease activity indices that 
are completely self-reported [8,9]. Self-report indices have 
the advantage that no laboratory values and no formal joint 
counts are required. However, many rheumatologists may be 
hesitant in omitting a joint count that is still seen as an 
important source of information. Regardless of the validated 
disease activity index used, adopting tight control principles 
may lead to a large benefit for patients in daily practice.
Conclusions
Inflammatory rheumatic diseases are generally diseases with 
variable presentation and, therefore, multiple outcomes are 
measured in most of these diseases. Because of the com­
plexity of the pathogenesis underlying the diseases, multiple 
clinical manifestations are measured as a proxy for the patho­
genic process. Beyond manifestations of the disease process, 
rheumatic diseases can have several different consequences,
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Tab le  6
D isease a c tiv ity  ins trum en ts  in  th e  ACR gu ide lines
Instrument Range Low
Thresholds of disease activity 
Moderate High
Disease Activity Score in 28 joints 0 to 9.4 <3.2 >3.2 and <5.1 >5.1
Simplified Disease Activity Index 0.1 to 86.0 <11 >11 and <26 >26
Clinical Disease Activity Index 0 to 76 <10 >10  and <22 >22
Rheumatoid Arthritis Disease Activity Index 0 to 10 <2.2 >2.2 and <4.9 >4.9
Patient Activity Scale 0 to 10 <1.9 >1.9 and <5.3 >5.3
Routine Assessment Patient Index Data 0 to 30 <6 >6 and <12 >12
Reprinted from [43] with permission of John Wiley & Sons, Inc.
making multiple outcomes relevant, including discomfort, 
disability, organ damage, and death; these may also include 
complications.
One of the challenges in facing multiple measurements is: 
should outcome measures be combined and, if yes, how? 
The development of pooled indices in RA is an outstanding 
example of this. Many developments in outcome measure­
ment of rheumatic diseases started in RA and have been 
applied to other rheumatic diseases. However, in rheumatic 
diseases in which multiple organ systems are involved, such 
as psoriatic arthritis or systemic sclerosis, the combination of 
outcome measures is not straightforward. Developing 
outcome measures for diseases meeting new treatment 
targets will be of growing importance in the next decade.
In the next decade success of therapeutic strategies will be 
measured by the percentage of patients reaching remission 
or at least reaching a very low disease activity state, and not 
by how many patients improved by a certain amount. Indeed, 
for RA as well as other rheumatic diseases, the clinically most 
meaningful outcome measure is a state measure of disease 
activity, whilst the most efficient outcome measure for clinical 
trials is a continuous measure of change. Therefore, for 
clinical trials a continuous measure of change may be 
preferred as the primary outcome measure, and a measure of 
state may be preferred as the secondary outcome measure. It 
is an advantage when both the primary and secondary 
outcome measures are simply variations of the same 
measure, which should be meaningful in daily practice. In 
cohorts and in daily practice, state measures that can be 
converted to the same change measure as in trials are useful 
as the use of the same measures in trials, cohorts and 
practice promotes knowledge transfer.
Following treatment success in RA, the vision of pharma­
cological treatment in the inflammatory rheumatic diseases 
nowadays has become reaching and sustaining remission. 
Clinical remission, meaning absence of clinically visible
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disease manifestations, including the condition that disease 
consequences do not occur, may be a reasonable target for a 
start. When disease manifestations are reduced to subclinical 
levels, this raises additional interest in biomarkers and 
imaging techniques for outcome measurement. Finding 
biomarkers and imaging techniques that are suited for use in 
daily clinical practice will become even more important. How­
ever, for daily clinical practice, outcome measures should be 
feasible and meaningful: feasible to perform in busy daily 
clinical practice, and meaningful to be able to steer treatment 
decisions. At this point, patient-reported outcomes and easily 
derivable clinical indices have an advantage in this regard.
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